A detailed history of Morgan Stanley transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 33,692 shares of CUE stock, worth $33,692. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,692
Previous 120,999 72.16%
Holding current value
$33,692
Previous $150,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.45 - $1.08 $39,288 - $94,291
-87,307 Reduced 72.16%
33,692 $25,000
Q2 2024

Oct 17, 2024

SELL
$1.24 - $2.18 $35,807 - $62,951
-28,877 Reduced 19.27%
120,999 $150,000
Q2 2024

Aug 14, 2024

SELL
$1.24 - $2.18 $35,807 - $62,951
-28,877 Reduced 19.27%
120,999 $150,000
Q1 2024

Oct 17, 2024

BUY
$1.77 - $3.09 $51,112 - $89,229
28,877 Added 23.87%
149,876 $283,000
Q1 2024

Aug 16, 2024

SELL
$1.77 - $3.09 $26,249 - $45,824
-14,830 Reduced 9.0%
149,876 $283,000
Q1 2024

May 15, 2024

SELL
$1.77 - $3.09 $26,249 - $45,824
-14,830 Reduced 9.0%
149,876 $283,000
Q4 2023

Aug 16, 2024

BUY
$1.72 - $3.1 $75,176 - $135,491
43,707 Added 36.12%
164,706 $434,000
Q4 2023

Feb 13, 2024

BUY
$1.72 - $3.1 $69,088 - $124,520
40,168 Added 32.25%
164,706 $434,000
Q3 2023

Nov 15, 2023

BUY
$2.23 - $4.69 $41,756 - $87,820
18,725 Added 17.7%
124,538 $286,000
Q2 2023

Aug 14, 2023

BUY
$3.11 - $4.91 $21,421 - $33,820
6,888 Added 6.96%
105,813 $386,000
Q1 2023

May 15, 2023

SELL
$2.41 - $3.74 $192,489 - $298,717
-79,871 Reduced 44.67%
98,925 $353,000
Q4 2022

Feb 14, 2023

SELL
$2.39 - $3.95 $182,863 - $302,222
-76,512 Reduced 29.97%
178,796 $509,000
Q3 2022

Nov 14, 2022

SELL
$2.23 - $3.37 $402,011 - $607,523
-180,274 Reduced 41.39%
255,308 $569,000
Q2 2022

Oct 27, 2022

BUY
$2.49 - $5.92 $590,137 - $1.4 Million
237,003 Added 119.35%
435,582 $1.09 Million
Q2 2022

Aug 15, 2022

BUY
$2.49 - $5.92 $590,137 - $1.4 Million
237,003 Added 119.35%
435,582 $1.09 Million
Q1 2022

Oct 27, 2022

SELL
$4.41 - $12.28 $1.05 Million - $2.91 Million
-237,003 Reduced 54.41%
198,579 $969,000
Q1 2022

May 13, 2022

BUY
$4.41 - $12.28 $95,961 - $267,212
21,760 Added 12.31%
198,579 $969,000
Q4 2021

Feb 14, 2022

SELL
$10.86 - $17.85 $3.23 Million - $5.31 Million
-297,412 Reduced 62.71%
176,819 $2 Million
Q3 2021

Nov 15, 2021

BUY
$10.06 - $15.3 $4.77 Million - $7.26 Million
474,231 New
474,231 $6.91 Million

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $35.4M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.